Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. Online ahead of print.ABSTRACTAdjuvant endocrine therapy represents the standard of care for almost all HR+/HER2- breast cancers and different agents and durations are currently available. In this context, the tailoring and optimization of adjuvant endocrine treatment by reducing unnecessary toxic treatment while taking into account the biological heterogeneity of HR+/HER2- breast cancer represents a clinical priority. There is therefore a significant need for the integration of biological biomarkers in the choice of adjuvant endocrine therapy beyond current...
Source: Clinical Cancer Research - April 24, 2024 Category: Cancer & Oncology Authors: Michele Bottosso Federica Miglietta Grazia Maria Vernaci Tommaso Giarratano Maria Vittoria Dieci Valentina Guarneri Gaia Griguolo Source Type: research
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2 α in Patients with Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: ARO-HIF2 downregulated HIF2α in advanced ccRCC-inhibiting tumor growth in a subset of subjects. Further development was hampered by off-target neurotoxicity and low response rate. This study provides proof of concept that siRNA can target tumors in a specific manner.PMID:38652038 | DOI:10.1158/1078-0432.CCR-23-3029 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: James Brugarolas Gregory Obara Kathryn E Beckermann Brian Rini Elaine T Lam James Hamilton Thomas Schluep Min Yi So Wong Zhongping Lily Mao Erick Gamelin Nizar M Tannir Source Type: research
FLT3 agonists and secondary hematopoietic malignancies: a potential class effect
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research
Classifying glioma via liquid biopsy--progress towards an unmet clinical need
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0423. Online ahead of print.ABSTRACTThe diagnosis and classification of glioma by liquid biopsy represents a critical unmet need in neuro oncology. A recent study demonstrates targeted next generation sequencing (NGS) of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) as an evolving option for liquid biopsy in patients with glioma.PMID:38652677 | DOI:10.1158/1078-0432.CCR-24-0423 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Kalil G Abdullah Source Type: research
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
CONCLUSIONS: Genomic profiling can contextualize the advantage of early intervention in SMM and guide personalization of therapy.PMID:38652812 | DOI:10.1158/1078-0432.CCR-24-0210 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Dickran Kazandjian Benjamin Diamond Marios Papadimitriou Elizabeth Hill Romanos Sklavenitis-Pistofidis Bachisio Ziccheddu Patrick Blaney Monika Chojnacka Michael Durante Kylee Maclachlan Ryan Young Saad Usmani Faith Davies Gad Getz Irene Ghobrial Neha Kor Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study
CONCLUSIONS: Utilizing the split-course hypo-RT and hypo-boost approach, a fraction dose of 5Gy to a total dose of 60Gy, combined with concurrent chemotherapy and subsequent cICI, was well-tolerated, and yielded promising ORR and survival outcomes.PMID:38652815 | DOI:10.1158/1078-0432.CCR-23-3600 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Rui Zhou FangJie Liu HongMei Zhang DaQuan Wang PengXin Zhang ShiYang Zheng YiMei Liu Li Chen JinYu Guo YingYi Zou Yu-Ming Rong Hui Liu Bo Qiu Source Type: research
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2 α in Patients with Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: ARO-HIF2 downregulated HIF2α in advanced ccRCC-inhibiting tumor growth in a subset of subjects. Further development was hampered by off-target neurotoxicity and low response rate. This study provides proof of concept that siRNA can target tumors in a specific manner.PMID:38652038 | DOI:10.1158/1078-0432.CCR-23-3029 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: James Brugarolas Gregory Obara Kathryn E Beckermann Brian Rini Elaine T Lam James Hamilton Thomas Schluep Min Yi So Wong Zhongping Lily Mao Erick Gamelin Nizar M Tannir Source Type: research
FLT3 agonists and secondary hematopoietic malignancies: a potential class effect
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0460. Online ahead of print.ABSTRACTExpansion of cDC cells via FLT3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. Here, we discuss the results of a clinical trial using GS-3583, an FLT3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia.PMID:38652676 | DOI:10.1158/1078-0432.CCR-24-0460 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Henry W Raeder Michael W Drazer Source Type: research
Classifying glioma via liquid biopsy--progress towards an unmet clinical need
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0423. Online ahead of print.ABSTRACTThe diagnosis and classification of glioma by liquid biopsy represents a critical unmet need in neuro oncology. A recent study demonstrates targeted next generation sequencing (NGS) of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) as an evolving option for liquid biopsy in patients with glioma.PMID:38652677 | DOI:10.1158/1078-0432.CCR-24-0423 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Kalil G Abdullah Source Type: research
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma
CONCLUSIONS: Genomic profiling can contextualize the advantage of early intervention in SMM and guide personalization of therapy.PMID:38652812 | DOI:10.1158/1078-0432.CCR-24-0210 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Dickran Kazandjian Benjamin Diamond Marios Papadimitriou Elizabeth Hill Romanos Sklavenitis-Pistofidis Bachisio Ziccheddu Patrick Blaney Monika Chojnacka Michael Durante Kylee Maclachlan Ryan Young Saad Usmani Faith Davies Gad Getz Irene Ghobrial Neha Kor Source Type: research
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
CONCLUSIONS: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.PMID:38652814 | DOI:10.1158/1078-0432.CCR-23-3431 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Mario E Lacouture Elena Goleva Neil Shah Veronica Rotemberg Lukas Kraehenbuehl Kwami F Ketosugbo Taha Merghoub Tara Maier Alexander Bang Stephanie Gu Trina Salvador Andrea P Moy Taras Lyubchenko Olivia Xiao Clifton F Hall Evgeny Berdyshev James Crooks Rya Source Type: research
Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study
CONCLUSIONS: Utilizing the split-course hypo-RT and hypo-boost approach, a fraction dose of 5Gy to a total dose of 60Gy, combined with concurrent chemotherapy and subsequent cICI, was well-tolerated, and yielded promising ORR and survival outcomes.PMID:38652815 | DOI:10.1158/1078-0432.CCR-23-3600 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: Rui Zhou FangJie Liu HongMei Zhang DaQuan Wang PengXin Zhang ShiYang Zheng YiMei Liu Li Chen JinYu Guo YingYi Zou Yu-Ming Rong Hui Liu Bo Qiu Source Type: research
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
CONCLUSIONS: ML modeling effectively subclassified patients with BCLC-C HCC, potentially aiding treatment allocation. Our study underscores the potential utilization of ML modeling in terms of prognostication and treatment allocation in patients with BCLC-C HCC.PMID:38639918 | DOI:10.1158/1078-0432.CCR-23-3978 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 19, 2024 Category: Cancer & Oncology Authors: Ji Won Han Soon Kyu Lee Jung Hyun Kwon Soon Woo Nam Hyun Yang Si Hyun Bae Ji Hoon Kim Heechul Nam Chang Wook Kim Hae Lim Lee Hee Yeon Kim Sung Won Lee Ahlim Lee U Im Chang Do Seon Song Seok-Hwan Kim Myeong Jun Song Pil Soo Sung Jong Young Choi Seung Kew Y Source Type: research
Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma
CONCLUSIONS: Collectively, our findings suggest NeoVax did stimulate expansion of neoantigen-specific effector T cells and provide encouraging results to aid in the development of future neoantigen vaccine-based clinical trials in patients with GBM. Herein, we demonstrate the feasibility of incorporating multisector sampling in cancer vaccine design and provide information on the clinical applicability of clonality, distribution, and immunogenicity of the neoantigen landscape in GBM patients.PMID:38639919 | DOI:10.1158/1078-0432.CCR-23-3077 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 19, 2024 Category: Cancer & Oncology Authors: Tanner M Johanns Elizabeth A R Garfinkle Katherine E Miller Alexandra J Livingstone Kaleigh F Roberts Lakshmi Prakruthi Rao Venkata Joshua L Dowling Michael R Chicoine Ralph G Dacey Gregory J Zipfel Albert H Kim Elaine R Mardis Gavin P Dunn Source Type: research
